Mechanisms of the Synergistic Interaction between the Bisphosphonate Zoledronic Acid and the Chemotherapy Agent Paclitaxel in Breast Cancer Cells in vitro
Authors:
- C.A. EvansCEC.A. Evans
- R.E. ColemanRCR.E. Coleman
- I. HolenIHI. Holen
- 1 January 2006
- journal article
- research article
- Published by Springer Nature in Tumor Biology
- Vol. 27 (2) , 92-103
Abstract
Breast cancer patients often receive both paclitaxel and zoledronic acid as part of their treatment, and these drugs are reported to have synergistic effects on the induction of apoptosis of breast cancer cells in vitro. We have found that the synergistic interaction is drug sequence dependent, with maximal levels of apoptosis achieved when cells are treated with paclitaxel followed by zoledronic acid, as opposed to the reverse sequence or simultaneous treatment. The synergistic interaction persists at clinically relevant concentrations and incubation periods. We report that the sequential treatment is associated with cell cycle changes and depends on breast cancer cell characteristics, with hormone independence, mutated p53 status and presence of BRCA1 gene being associated with higher levels of apoptosis. Finally, we have found that the synergistic induction of apoptosis is via zoledronic acid-mediated inhibition of the mevalonate pathway.Keywords
This publication has 24 references indexed in Scilit:
- The anti-tumour activity of bisphosphonatesCancer Treatment Reviews, 2002
- Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic AcidThe Journal of Pharmacology and Experimental Therapeutics, 2002
- A Multistep Model for Paclitaxel-Induced Apoptosis in Human Breast Cancer Cell LinesExperimental Cell Research, 2001
- The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxelBritish Journal of Cancer, 2001
- Bisphosphonates induce apoptosis in human breast cancer cell linesBritish Journal of Cancer, 2000
- Zoledronate Is a Potent Inhibitor of Myeloma Cell Growth and Secretion of IL-6 and MMP-1 by the Tumoral EnvironmentJournal of Bone and Mineral Research, 1999
- Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrestBritish Journal of Cancer, 1998
- Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti‐tumour activityBritish Journal of Haematology, 1997
- Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.Journal of Clinical Investigation, 1996
- Promotion of microtubule assembly in vitro by taxolNature, 1979